DIVISIONS

The Westaim Corporation invests, directly and indirectly, through acquisitions, joint ventures and other arrangements, with the objective of providing its shareholders with capital appreciation and real wealth preservation. Westaim holds a 75 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Westaim's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.

 

NUCRYST Pharmaceuticals researches, develops and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology.